In KRAS-mutated colorectal carcinoma, Cetuximab, an anti-EGFR antibody, leads to the depletion of Glutathione (GSH) when combined with β-Elemene by inducing the iron-dependent accumulation of reactive oxygen species [125]. This evidence concerns the gene KRAS and colorectal carcinoma.